In addition, FBXW7 has been shown to regulate solid tumor tolerance to immune checkpoint inhibitors (ICIs) and anti-PD-L1 therapy by blocking the nuclear factor of activated T cell 1 (NFAT1)/PD-L1 axis [117], which also offers new insights into the improvement of immunotherapeutic agents for breast cancer from the perspective of targeting FBXW7. Here, CD274 is linked to breast carcinoma.